IDOV-Immune
AXP000110.1 · Oncolytic virus
- Platform
- vaccinia virus
- Originator
- ViroMissile
- Sponsor
- ViroMissile
Names
| Name | Type | Source |
|---|---|---|
| IDOV-Immune | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Replication
- conditionally replicating
- Modifications
- not described in the registration
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07656090 | Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors | Enrolling by invitation | Early phase 1 | 2025-12-18 | 2027-10-31 | 19 | Cancer |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | Recruiting | Phase 1 | 2025-08-25 | 2027-01-31 | 78 | Adrenal Gland Tumors; Bladder Cancer; Breast Cancer; Cervical Cancers; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancers; Hepatocellular Carcinoma; Lung Cancer; Melanoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cell Carcinoma; Sarcoma |
Recent changes
No changes recorded in its trials yet.
Notes
First-in-human phase 1 oncolytic vaccinia (NCT06910657, recruiting since April 2025). The related ViroMissile candidate IDOV-SAFE is a separate program on the same platform.
How to cite
IDOV-Immune (AXP000110.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000110.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.